Insight into genetic predisposition to chronic lymphocytic leukemia from integrative epigenomics.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
09 08 2019
Historique:
received: 13 07 2018
accepted: 23 07 2019
entrez: 11 8 2019
pubmed: 11 8 2019
medline: 18 12 2019
Statut: epublish

Résumé

Genome-wide association studies have provided evidence for inherited genetic predisposition to chronic lymphocytic leukemia (CLL). To gain insight into the mechanisms underlying CLL risk we analyze chromatin accessibility, active regulatory elements marked by H3K27ac, and DNA methylation at 42 risk loci in up to 486 primary CLLs. We identify that risk loci are significantly enriched for active chromatin in CLL with evidence of being CLL-specific or differentially regulated in normal B-cell development. We then use in situ promoter capture Hi-C, in conjunction with gene expression data to reveal likely target genes of the risk loci. Candidate target genes are enriched for pathways related to B-cell development such as MYC and BCL2 signalling. At 14 loci the analysis highlights 63 variants as the probable functional basis of CLL risk. By integrating genetic and epigenetic information our analysis reveals novel insights into the relationship between inherited predisposition and the regulatory chromatin landscape of CLL.

Identifiants

pubmed: 31399598
doi: 10.1038/s41467-019-11582-2
pii: 10.1038/s41467-019-11582-2
pmc: PMC6689100
doi:

Substances chimiques

BCL2 protein, human 0
Chromatin 0
MYC protein, human 0
Proto-Oncogene Proteins c-bcl-2 0
Proto-Oncogene Proteins c-myc 0
Transcription Factors 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3615

Subventions

Organisme : Blood Cancer UK
ID : 06002
Pays : United Kingdom
Organisme : Blood Cancer UK
ID : 13044
Pays : United Kingdom

Références

Immunity. 2000 Jul;13(1):15-24
pubmed: 10933391
PLoS Comput Biol. 2010 May 06;6(5):e1000770
pubmed: 20463871
Blood. 2004 Sep 15;104(6):1850-4
pubmed: 15161669
PLoS Genet. 2009 Jun;5(6):e1000529
pubmed: 19543373
Nat Genet. 2013 Aug;45(8):868-76
pubmed: 23770605
Nat Methods. 2012 Mar 04;9(4):357-9
pubmed: 22388286
Nat Genet. 2016 Jun;48(6):667-674
pubmed: 27135401
Nat Commun. 2017 Feb 06;8:14175
pubmed: 28165464
Trends Mol Med. 2014 Jun;20(6):343-52
pubmed: 24698494
Elife. 2016 May 10;5:
pubmed: 27162171
Nat Rev Immunol. 2008 Jul;8(7):559-68
pubmed: 18575461
Bioinformatics. 2009 Jul 15;25(14):1754-60
pubmed: 19451168
N Engl J Med. 2016 Jan 28;374(4):311-22
pubmed: 26639348
Nat Methods. 2015 Nov;12(11):1061-3
pubmed: 26366987
Mol Cell. 2017 Jul 20;67(2):181-193.e5
pubmed: 28689657
Nat Genet. 2015 Jul;47(7):746-56
pubmed: 26053498
Genome Biol. 2016 Jun 15;17(1):127
pubmed: 27306882
Cell. 2014 Dec 18;159(7):1665-80
pubmed: 25497547
Nat Genet. 2014 Jan;46(1):56-60
pubmed: 24292274
Blood. 2011 Feb 10;117(6):1911-6
pubmed: 21131588
Nat Genet. 2012 Nov;44(11):1236-42
pubmed: 23064414
Bioinformatics. 2012 May 15;28(10):1353-8
pubmed: 22492648
Genome Biol. 2014;15(12):550
pubmed: 25516281
Nat Rev Genet. 2013 Jun;14(6):390-403
pubmed: 23657480
Cell Rep. 2016 Aug 23;16(8):2061-2067
pubmed: 27524613
Nat Genet. 2015 Jun;47(6):598-606
pubmed: 25938943
Nat Genet. 2008 Oct;40(10):1204-10
pubmed: 18758461
Bioinformatics. 2015 Dec 1;31(23):3847-9
pubmed: 26272984
Nat Protoc. 2010 Sep;5(9):1564-73
pubmed: 21085122
Nature. 2010 Apr 15;464(7291):993-8
pubmed: 20393554
Cell. 2016 Nov 17;167(5):1369-1384.e19
pubmed: 27863249
Annu Rev Immunol. 2018 Apr 26;36:489-517
pubmed: 29400998
Sci Immunol. 2017 Mar 3;2(9):
pubmed: 28783698
Front Biol (Beijing). 2014 Aug;9(4):269-282
pubmed: 25506356
Nucleic Acids Res. 2014 Mar;42(5):2976-87
pubmed: 24335146
Am J Hum Genet. 2007 Sep;81(3):559-75
pubmed: 17701901
Nat Genet. 2010 Feb;42(2):132-6
pubmed: 20062064
F1000Res. 2015 Nov 20;4:1310
pubmed: 26835000
Blood. 2011 Jun 9;117(23):6287-96
pubmed: 21422473
Nat Commun. 2016 Mar 09;7:10933
pubmed: 26956414
Nature. 2017 Nov 2;551(7678):92-94
pubmed: 29059683
Nat Genet. 2010 May;42(5):436-40
pubmed: 20418889
Bioinformatics. 2015 Nov 1;31(21):3555-7
pubmed: 26139635
J Natl Cancer Inst. 2019 Feb 1;111(2):146-157
pubmed: 29917119
Nat Rev Cancer. 2017 Nov;17(11):692-704
pubmed: 29026206
Blood. 2012 Jul 26;120(4):843-6
pubmed: 22700719
Nat Commun. 2015 Sep 14;6:8111
pubmed: 26368830
Nature. 2015 Oct 22;526(7574):519-24
pubmed: 26200345
Nat Genet. 2007 Jul;39(7):906-13
pubmed: 17572673
Nat Med. 2018 Jun;24(6):868-880
pubmed: 29785028

Auteurs

Helen E Speedy (HE)

Division of Genetics and Epidemiology, Institute of Cancer Research, London, SW7 3RP, UK.

Renée Beekman (R)

Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036, Barcelona, Spain.
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 28029, Madrid, Spain.

Vicente Chapaprieta (V)

Departament de Fonaments Clinics, Facultat de Medicina, Universitat de Barcelona, 08036, Barcelona, Spain.

Giulia Orlando (G)

Division of Genetics and Epidemiology, Institute of Cancer Research, London, SW7 3RP, UK.

Philip J Law (PJ)

Division of Genetics and Epidemiology, Institute of Cancer Research, London, SW7 3RP, UK.

David Martín-García (D)

Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036, Barcelona, Spain.
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 28029, Madrid, Spain.

Jesús Gutiérrez-Abril (J)

Departamento de Bioquímica y Biología Molecular, Instituto Universitario de Oncología (IUOPA), Universidad de Oviedo, 33006, Oviedo, Spain.

Daniel Catovsky (D)

Division of Genetics and Epidemiology, Institute of Cancer Research, London, SW7 3RP, UK.

Sílvia Beà (S)

Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036, Barcelona, Spain.
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 28029, Madrid, Spain.

Guillem Clot (G)

Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036, Barcelona, Spain.
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 28029, Madrid, Spain.

Montserrat Puiggròs (M)

Programa Conjunto de Biología Computacional, Barcelona Supercomputing Center (BSC), Institut de Recerca Biomèdica (IRB), Spanish National Bioinformatics Institute, Universitat de Barcelona, Barcelona, Spain.

David Torrents (D)

Programa Conjunto de Biología Computacional, Barcelona Supercomputing Center (BSC), Institut de Recerca Biomèdica (IRB), Spanish National Bioinformatics Institute, Universitat de Barcelona, Barcelona, Spain.
Institució Catalana de Recerca i Estudis Avançats (ICREA), 08010, Barcelona, Spain.

Xose S Puente (XS)

Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 28029, Madrid, Spain.
Departamento de Bioquímica y Biología Molecular, Instituto Universitario de Oncología (IUOPA), Universidad de Oviedo, 33006, Oviedo, Spain.

James M Allan (JM)

Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, NE2 4HH, UK.

Carlos López-Otín (C)

Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 28029, Madrid, Spain.
Departamento de Bioquímica y Biología Molecular, Instituto Universitario de Oncología (IUOPA), Universidad de Oviedo, 33006, Oviedo, Spain.

Elias Campo (E)

Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036, Barcelona, Spain.
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 28029, Madrid, Spain.
Departament de Fonaments Clinics, Facultat de Medicina, Universitat de Barcelona, 08036, Barcelona, Spain.
Hematopathology Section, Hospital Clinic of Barcelona, 08036, Barcelona, Spain.

Richard S Houlston (RS)

Division of Genetics and Epidemiology, Institute of Cancer Research, London, SW7 3RP, UK. richard.houlston@icr.ac.uk.

José I Martín-Subero (JI)

Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036, Barcelona, Spain. imartins@clinic.cat.
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 28029, Madrid, Spain. imartins@clinic.cat.
Departament de Fonaments Clinics, Facultat de Medicina, Universitat de Barcelona, 08036, Barcelona, Spain. imartins@clinic.cat.
Institució Catalana de Recerca i Estudis Avançats (ICREA), 08010, Barcelona, Spain. imartins@clinic.cat.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH